Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting
May 27, 2014The data from Syndax Pharmaceuticals’ phase 1 and 2 clinical trials on entinostat will be presented in two posters during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 – June 3, 2014, in Chicago.
More »
Celator® Pharmaceuticals Announces Publication of Positive Phase 2 Data With CPX-351 in Acute Myeloid Leukemia Patients
May 27, 2014Celator® Pharmaceuticals announced the Phase 2 data of CPX-351 for the treatment of newly diagnosed acute myeloid leukemia (AML) in older patients. This data was published in Blood, the official journal of the American Society of Hematology.
More »
FDA Approves Durata Therapeutics’ DALVANCE™ for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-positive Bacteria, Including MRSA, in Adults
May 23, 2014The FDA approved Durata Therapeutics’ DALVANCE™ (dalbavancin). This is the first and only IV antibiotic approved treatment for adult acute bacterial skin and skin structure infections (ABSSSI) with a unique and efficient three-dose regimen.
More »